These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38258125)

  • 1. Burst Release from In Situ Forming PLGA-Based Implants: 12 Effectors and Ways of Correction.
    Bakhrushina EO; Sakharova PS; Konogorova PD; Pyzhov VS; Kosenkova SI; Bardakov AI; Zubareva IM; Krasnyuk II; Krasnyuk II
    Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
    Desai KG; Mallery SR; Schwendeman SP
    Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.
    Desai KG; Mallery SR; Schwendeman SP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):187-98. PubMed ID: 18472254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
    Kranz H; Bodmeier R
    Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release.
    Parent M; Nouvel C; Koerber M; Sapin A; Maincent P; Boudier A
    J Control Release; 2013 Nov; 172(1):292-304. PubMed ID: 24001947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial Leuprolide Acetate Release from Poly(d,l-lactide-
    Li Z; Mu H; Larsen SW; Jensen H; Østergaard J
    Mol Pharm; 2020 Dec; 17(12):4522-4532. PubMed ID: 33164519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of implant formation on drug release kinetics of in situ forming implants.
    Suh MS; Kastellorizios M; Tipnis N; Zou Y; Wang Y; Choi S; Burgess DJ
    Int J Pharm; 2021 Jan; 592():120105. PubMed ID: 33232755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the design of in situ forming biodegradable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) nanoparticles.
    Packhaeuser CB; Kissel T
    J Control Release; 2007 Nov; 123(2):131-40. PubMed ID: 17854938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
    Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
    J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Drug Physicochemical Properties on In-Situ Forming Implant Polymer Degradation and Drug Release Kinetics.
    Joiner JB; Prasher A; Young IC; Kim J; Shrivastava R; Maturavongsadit P; Benhabbour SR
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
    Kranz H; Bodmeier R
    Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.
    Solorio L; Olear AM; Hamilton JI; Patel RB; Beiswenger AC; Wallace JE; Zhou H; Exner AA
    Theranostics; 2012; 2(11):1064-77. PubMed ID: 23227123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ forming risperidone implants: Effect of PLGA attributes on product performance.
    Wang X; Bao Q; Wang R; Kwok O; Maurus K; Wang Y; Qin B; Burgess DJ
    J Control Release; 2023 Sep; 361():777-791. PubMed ID: 37591464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems.
    Luan X; Bodmeier R
    J Control Release; 2006 Jan; 110(2):266-272. PubMed ID: 16300851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving release completeness from PLGA-based implants for the acid-labile model protein ovalbumin.
    Duque L; Körber M; Bodmeier R
    Int J Pharm; 2018 Mar; 538(1-2):139-146. PubMed ID: 29355654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro study on tamsulosin release kinetics from biodegradable PLGA in situ implants.
    Elias-Al-Mamun M; Khan HA; Dewan I; Jalil RU
    Pak J Pharm Sci; 2009 Oct; 22(4):360-7. PubMed ID: 19783512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved small molecule drug release from in situ forming poly(lactic-co-glycolic acid) scaffolds incorporating poly(β-amino ester) and hydroxyapatite microparticles.
    Fisher PD; Palomino P; Milbrandt TA; Hilt JZ; Puleo DA
    J Biomater Sci Polym Ed; 2014; 25(11):1174-93. PubMed ID: 24903524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase separation of in situ forming poly (lactide-co-glycolide acid) implants investigated using a hydrogel-based subcutaneous tissue surrogate and UV-vis imaging.
    Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
    J Pharm Biomed Anal; 2017 Oct; 145():682-691. PubMed ID: 28803207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Polymer Permeability and Solvent Removal Rate on
    Zhang X; Yang L; Zhang C; Liu D; Meng S; Zhang W; Meng S
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31658642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Lasting
    Bazraee S; Mobedi H; Mashak A; Jamshidi A
    Curr Drug Deliv; 2022; 19(1):157-166. PubMed ID: 34139983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.